The role of pharmacogenomics in metastatic renal cell carcinoma.

doi:10.1007/s10555-012-9356-x

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The role of pharmacogenomics in metastatic renal cell carcinoma.

Cancer metastasis reviews - 1 Sept 2012

Castellano Daniel, Virizuela Juan Antonio, Cruz Josefina, Sepulveda Juan Manuel, Sáez María Isabel, Sáenz Maribel, Paz-Ares Luís

Abstract excerpt

Pharmacogenomics is the study of how variation in the genetic background affects an individual's response to a specific drug and/or its metabolism. Using knowledge about the genes which produce the enzymes that metabolize a specific drug, a physician may decide to raise or lower the dose, or even change to a different drug. Targeted therapy with tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Renal Cell
Share to Drug Delivery Systems
Share to Kidney Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Metastasis

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Share to Protein Kinase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 22723081
DOI: 10.1007/s10555-012-9356-x

Genes

FGFR2
FLT4
VEGFA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.